Biomea Fusion's Oral GLP-1 Receptor Agonist, BMF-650, Shows Promising Phase 1 Weight Reduction and Tolerability

Biomea Fusion, Inc. has announced positive Phase 1 clinical trial results for BMF-650, an investigational oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The study demonstrated consistent weight reduction, with participants experiencing a mean weight loss ranging from 1.5% to 3.2% at Day 29 across multiple ascending dose cohorts, compared to 0.1% for the placebo group. The drug also exhibited encouraging tolerability, with all reported treatment-emergent adverse events being mild or moderate, even with rapid dose titration. These preliminary findings support further evaluation of BMF-650 for weight management.